PROSTATE CANCER: EPIDEMOLOGIC AND CLINICAL MARKERS

前列腺癌：流行病学和临床标志物

• 批准号: 6563953
• 负责人: Sara S. Strom
• 金额: $ 29.18万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-01-24 至 2002-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6563953
• 关键词: angiogenesis; biomarker; cancer prevention; disease /disorder etiology; disease /disorder proneness /risk; gene expression; genetic markers; human genetic material tag; human subject; in situ hybridization; interview; male; metastasis; microarray technology; neoplasm /cancer classification /staging; neoplasm /cancer epidemiology; neoplasm /cancer therapy; neoplastic process; nucleic acid purification; nucleic acid sequence; outcomes research; patient oriented research; prostate neoplasms; questionnaires; racial /ethnic difference; statistics /biometry

A critical goal in prostate cancer (PC) research is to identify epidemiological, clinical and molecular markers related to PC progression. We propose to conduct a follow-up study of 1200 PC patients of all ethnicities seen at U.T.M.D. Anderson Cancer Center between 1990 and 2000. These men are participants in our ongoing epidemiological studies for whom we have collected baseline clinical and epidemiological information and for whom banked specimens (DNA and tissue) are available. The objective is to identify clinical, lifestyle, and genetic factors that may play a role in disease progression. Our first aim is to evaluate baseline epidemiologic (smoking, BMI, family history of PC), clinical (stage, Gleason score, tumor volume) and treatment parameters and their impact on PC progression. We will collect information on health status through telephone interviews. Recurrence, biochemical failure, and death will be verified through medical records and death certificates. Aim 2 will evaluate genetic susceptibility by genotyping patients for polymorphic genes related to hormone metabolism: androgen receptor, 5-alpha-reductase type II, CYPO17, CYP3A4, 3-beta-hydroxysteroid dehydrogenase type II, and vitamin D receptor. In aim 3, we will create tissue microarrays to allow the analysis of gene expression by in situ hybridization for a panel for tumor progression markers (e.g., MMP-2, MMP-9, VEGF, and E-cadherin) in a subset of 375 cases of indifferent ethnicity (200 whites, 100 African Americans, and 75 Hispanics). Finally, we will integrate these molecular, epidemiologic and clinical data to investigate how the interplay between these characteristics modifies PC progression. Findings from this project could be useful in identifying patients at high risk of PC progression and could assist clinicians in determining the most appropriate strategy.

前列腺癌（PC）研究的一个关键目标是确定与PC进展相关的流行病学，临床和分子标志物。我们建议对在U.T.M.D.就诊的所有种族的1200例PC患者进行随访研究。安德森癌症中心1990年至2000年。 这些人是我们正在进行的流行病学研究的参与者，我们已经收集了他们的基线临床和流行病学信息，并提供了他们的库存标本（DNA和组织）。目的是确定可能在疾病进展中发挥作用的临床，生活方式和遗传因素。我们的首要目标是评估基线流行病学（吸烟，BMI，PC家族史），临床（分期，Gleason评分，肿瘤体积）和治疗参数及其对PC进展的影响。我们将通过电话访问收集有关健康状况的信息。复发、生化失败和死亡将通过医疗记录和死亡证明进行验证。目的2将通过对患者进行与激素代谢相关的多态性基因（雄激素受体、5-α-还原酶II型、CYPO 17、CYP 3A 4、3-β-羟基类固醇脱氢酶II型和维生素D受体）的基因分型来评估遗传易感性。在目标3中，我们将创建组织微阵列，以允许通过原位杂交分析肿瘤进展标志物组的基因表达（例如，MMP-2、MMP-9、VEGF和E-cadherin）在375例不同种族（200例白人、100例非洲裔美国人和75例西班牙裔美国人）的亚组中的表达。最后，我们将整合这些分子、流行病学和临床数据，研究这些特征之间的相互作用如何改变PC进展。该项目的发现可能有助于识别PC进展高风险患者，并可帮助临床医生确定最合适的策略。